Sector News

After R&D spree, Bayer changes up research unit

November 30, 2017
Life sciences

After penning research deals potentially worth billions of dollars this month, German pharma Bayer is looking internally as it rings in the changes.

In a major reorganization, Bayer says it will be combining its pharma R&D unit under one division and under one leader in a change-up reminiscent of what fellow European pharma Novartis did last year.

Joerg Moeller, currently head of development at Bayer’s pharmaceuticals division, will become that one leader, officially set to be the new head of research and development, and will start on New Year’s Day.

Andreas Busch, the head of drug discovery within the pharmaceuticals division of Bayer, will be leaving for “another company,” the company said in a statement, but would not say which one. He’s been in that position since 2014 and started at Bayer all the way back in 1993.

The new unit will combine all R&D activities for therapeutic areas across the board within the company’s pharmaceuticals division, including cardiology, gynecology, ophthalmology, hematology and oncology research .

“The combined organization will enable us to seamlessly steer all the important activities of Research and Development, with a single objective to further enhance the delivery of much needed new treatment options to patients,” explained Dieter Weinand, president of Bayer’s pharmaceuticals division.

“Joerg has an exceptional track record of bringing new medicines to patients, which have the potential to increase their quality of life and address serious medical conditions, and I trust that our team will be even more successful in doing so together under his leadership. At the same time, we thank Andreas Busch for all his valuable contributions to our company and wish him much success in his future endeavors.”

This comes in the same month that Bayer has been making some big bets in R&D, paying a few weeks back $400 million (€340 million) and putting a potential $1 billion more on the table to buy into Loxo Oncology’s tropomyosin receptor kinase (TRK) inhibitor franchise.

Just a week later, it signed a new and potentially major research pact with Japan’s PeptiDream, using its tech to find macrocyclic/constrained peptides against a whole load of targets.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach